Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Receivables - Net (2024 - 2025)

Historic Receivables - Net for Madrigal Pharmaceuticals (MDGL) over the last 2 years, with Q3 2025 value amounting to $113.3 million.

  • Madrigal Pharmaceuticals' Receivables - Net rose 27187.74% to $113.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.3 million, marking a year-over-year increase of 27187.74%. This contributed to the annual value of $53.8 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Madrigal Pharmaceuticals' Receivables - Net stood at $113.3 million, which was up 27187.74% from $79.2 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' 5-year Receivables - Net high stood at $113.3 million for Q3 2025, and its period low was $6.9 million during Q2 2024.